Integra Announces Amendment and Extension of Credit Facility and Private Placement of Convertible Senior Notes PRINCETON, N.J.

Integra Announces Amendment and Extension of Credit Facility and Private Placement of Convertible Senior Notes

PRINCETON, N.J., February 3, 2020 Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it has amended and extended its

credit facility and commenced a private offering of convertible senior notes.

Amendment and Extension of Credit Facility

Integra today announced that it has amended and extended its credit facility with a bank group led by Bank of America, N.A. The overall size of the credit

facility is approximately $2.2 billion and consists of a revolving line of credit of $1.3 billion and an $877.5 million term loan. The maturity of the credit facility was extended to February 3, 2025.

We are pleased to announce this two-year extension of our credit facility under favorable terms, said Carrie Anderson, chief financial officer,

Integra. With these new terms, we have strengthened our balance sheet and increased our flexibility to pursue our long-term revenue growth and profitability strategy. We appreciate the continued support and commitment from our lending

Borrowings from the credit facility will be used to cover fees and expenses incurred in connection with the credit facility, for general

corporate purposes and other permitted uses.

Private Placement of Convertible Senior Notes

Integra today announced that it has commenced a private offering, subject to market conditions, of $500,000,000 aggregate principal amount of convertible

senior notes due 2025 (the Notes ). Integra expects to grant the initial purchasers of the Notes a 13-day option to purchase up to an additional $75,000,000 aggregate principal amount of Notes.

The Notes will be senior, unsecured obligations of Integra, and interest will be payable semi-annually in arrears. The Notes will mature on August 15,

2025, unless earlier converted, repurchased or redeemed in accordance with the terms of the Notes. Prior to 5:00 p.m., New York City time, on the business day immediately preceding February 15, 2025, the Notes will be convertible at the option

of holders of the Notes only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until 5:00 p.m., New York City time, on the second scheduled trading day immediately preceding the maturity date. Upon

conversion, the Notes may be settled in shares of Integra s common stock, cash or a combination of cash and shares of the common stock, at the election of Integra. Prior to February 20, 2023, the Notes will not be redeemable. On or after

February 20, 2023, Integra may redeem for cash all or part of the Notes, at its option, if the last reported sale price of Integra s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days

(whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which Integra provides notice of redemption.

Holders of the Notes will have the right to require Integra to repurchase for cash all or a portion of their Notes at 100% of their principal amount, plus any

accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the Notes). Integra will also be required to increase the conversion rate for holders who convert their Notes in connection with

certain fundamental changes occurring prior to the maturity date or following delivery by Integra of a notice of redemption.

conversion rate, offering price and other terms are to be determined upon pricing of the Notes.

In connection with the pricing of the offering of the

Notes, Integra expects to enter into privately negotiated convertible note hedge transactions with dealers, which may include initial purchasers and/or their respective affiliates (the option counterparties ). These transactions are

expected generally to reduce potential dilution to Integra s common stock upon conversion of the Notes. Integra also expects to enter into warrant transactions with the option counterparties. The warrant transactions could separately have a

dilutive effect on Integra s common stock if the market price of Integra s common stock exceeds the strike price of the warrants.

In connection with establishing their initial hedge of the convertible note hedge and warrant transactions,

the option counterparties expect to enter into various derivative transactions with respect to Integra s common stock concurrently with or shortly after the pricing of the Notes. These activities could have the effect of increasing (or reducing

the size of any decrease in) the market price of Integra s common stock.

Integra intends to use:

If the initial purchasers exercise

their option to purchase additional Notes, Integra may sell additional warrants and use the net proceeds from the sale of the additional Notes, together with the proceeds from the additional warrants, to enter into additional convertible note hedge

transactions. In addition, if the initial purchasers exercise their option to purchase additional Notes, Integra may use the remainder of the net proceeds from the sale of the additional Notes and the additional warrants for general corporate

purposes, which may include the repayment of a portion of the indebtedness under Integra s senior credit facility.

The settlement of the share

repurchases from certain purchasers of Notes in privately negotiated transactions is conditioned upon the closing of the offering of the Notes. Integra expects the purchase price per share of common stock repurchased from certain purchasers of Notes

in privately negotiated transactions concurrently with the closing of the offering of the Notes to equal the closing price per share of Integra s common stock on the date of the pricing of the offering of the Notes. The purchase price per share

of the common stock repurchased through the ASR transaction will generally be equal to the average volume-weighted average price of Integra s common stock during a period beginning after the ASR transaction becomes effective, less a discount.

The exact number of shares repurchased pursuant to the ASR transaction will be determined based on such purchase price.

In connection with the ASR

transaction, the ASR counterparty or its affiliate expects to purchase or sell Integra s common stock in secondary market transactions during the term of the ASR transaction. These activities and Integra s repurchases of its common stock

may raise or maintain the market price of Integra s common stock or the Notes above market levels that otherwise would have prevailed or prevent or retard a decline in such market price. In the case of transactions in Integra s common

stock effected concurrently with the offering of the Notes, these transactions could affect the market price of Integra s common stock concurrently with, or shortly after, the pricing of the Notes, and could result in a higher effective

conversion price for the Notes.

The Notes will be offered to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under

the Securities Act of 1933, as amended (the Securities Act ). The Notes and the shares of Integra s common stock issuable upon conversion of the Notes, if any, are not being registered under the Securities Act of 1933, as amended, or

any state securities laws, and may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and any applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities, in

any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Integra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for

clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel , Bactiseal , Cadence , Certas ,

Codman , CUSA , DuraGen , DuraSeal , ICP Express , Integra ,

MediHoney , MicroFrance , PriMatrix , Salto Talaris , SurgiMend , TCC-EZ , Titan and VersaTru .

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that

involve risks and uncertainties and reflect the Company s judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these

forward-looking statements may contain words like will, believe, may, could, would, might, possible, should, expect, intend,

plan, anticipate, or continue, the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this press release include, but are not limited to,

the expectations, plans and prospects for the Company, including whether or not the Company will offer the Notes or consummate the offering, the anticipated terms of the Notes and the offering, the anticipated use of proceeds of the offering of the

Notes and the credit facility and the proposed share repurchase. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. These risks and uncertainties

include market conditions and other factors beyond the Company s control and the economic, competitive, governmental, technological and other factors identified under the heading Risk Factors included in Item 1A of Integra s

Annual Report on Form 10-K for the year ended December 31, 2018 and information contained in subsequent filings with the Securities and Exchange Commission. These forward-looking statements are made only

as of the date hereof, and Integra undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contacts:

Senior Vice President, Strategy, Treasury & Investor Relations

Director, Investor Relations

Senior Director, Global Corporate Communications